Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1996 3
1997 2
1998 5
2000 1
2003 1
2006 2
2007 5
2008 2
2010 1
2011 1
2012 4
2013 1
2014 1
2015 1
2016 2
2017 1
2018 4
2019 2
2020 4
2021 1
2022 4
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
van der Straten L, Stege CAM, Kersting S, Nasserinejad K, Dubois J, Dobber JA, Mellink CHM, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken JH, Levenga H, Tick LW, Terpstra WE, Tonino SH, Westerweel PE, Langerak AW, Kater AP, Levin MD. van der Straten L, et al. Among authors: koene hr. Blood. 2023 Sep 28;142(13):1131-1142. doi: 10.1182/blood.2023020195. Blood. 2023. PMID: 37363833
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP; HOVON CLL study group. Kersting S, et al. Among authors: koene hr. Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5. Lancet Haematol. 2022. PMID: 35240075 Clinical Trial.
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV, Duetz C, Bruins WSC, Korst CLBM, Rentenaar R, Cosovic M, Eken M, Twickler I, Nijland M, van der Poel MWM, de Heer K, Klerk CPW, Strobbe L, Oosterveld M, Boersma R, Koene HR, Roemer MGM, van Werkhoven E, Chamuleau MED, Mutis T. de Jonge AV, et al. Among authors: koene hr. Blood Adv. 2024 Mar 12;8(5):1094-1104. doi: 10.1182/bloodadvances.2023011687. Blood Adv. 2024. PMID: 38191686 Free PMC article.
Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
van Dijk WEM, Poolen GC, Huisman A, Koene HR, Fijnheer R, Thielen N, van Bladel ER, van Galen KPM, Schutgens REG, Urbanus RT. van Dijk WEM, et al. Among authors: koene hr. J Thromb Haemost. 2023 Apr;21(4):1020-1031. doi: 10.1016/j.jtha.2022.11.039. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696209 Free article.
[Systematic diagnosis of erythrocytosis].
de Heer K, Silbermann MH, Koene HR, Biemond BJ, Muller HP, van Oers MH. de Heer K, et al. Among authors: koene hr. Ned Tijdschr Geneeskd. 2007 Aug 11;151(32):1770-6. Ned Tijdschr Geneeskd. 2007. PMID: 17822247 Review. Dutch.
Nutrition-related problems, nutritional support practices and barriers to adherence to nutritional guidelines during intensive treatment for acute myeloid leukemia: Patients' and hematology nurses' perspectives and experiences.
van Lieshout R, Lize N, Tick LW, van Deursen J, Driessen E, Janssen T, Custers S, Kranenburg S, van der Lee D, Koene HR, Beckers EAM, Schouten HC, Beijer S. van Lieshout R, et al. Among authors: koene hr. Clin Nutr ESPEN. 2022 Apr;48:446-455. doi: 10.1016/j.clnesp.2021.12.029. Epub 2022 Jan 1. Clin Nutr ESPEN. 2022. PMID: 35331527
53 results